Data-driven translational prostate cancer research: from biomarker discovery to clinical decision

被引:21
作者
Lin, Yuxin [1 ]
Zhao, Xiaojun [1 ]
Miao, Zhijun [2 ]
Ling, Zhixin [1 ]
Wei, Xuedong [1 ]
Pu, Jinxian [1 ]
Hou, Jianquan [1 ]
Shen, Bairong [3 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Dept Urol, Suzhou 215006, Peoples R China
[2] Suzhou Dushuhu Publ Hosp, Dept Urol, Suzhou 215123, Peoples R China
[3] Sichuan Univ, Inst Syst Genet, West China Hosp, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
Prostate cancer; Translational informatics; Biomarker discovery; Systems medicine; Clinical application; URINARY-TRACT SYMPTOMS; QUALITY-OF-LIFE; BIOCHEMICAL RECURRENCE; INTEGRATIVE ANALYSIS; RISK MEN; HEALTH; GENE; PROGRESSION; PREDICTION; DIAGNOSIS;
D O I
10.1186/s12967-020-02281-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big data-driven and systems-level screening. Complex interactions between genetic factors and environmental effects provide opportunities for systems modeling of PCa genesis and evolution. We hereby review the current research frontiers in informatics for PCa clinical translation. First, the heterogeneity and complexity in PCa development and clinical theranostics are introduced to raise the concern for PCa systems biology studies. Then biomarkers and risk factors ranging from molecular alternations to clinical phenotype and lifestyle changes are explicated for PCa personalized management. Methodologies and applications for multi-dimensional data integration and computational modeling are discussed. The future perspectives and challenges for PCa systems medicine and holistic healthcare are finally provided.
引用
收藏
页数:17
相关论文
共 109 条
  • [1] Exposure to polychlorinated biphenyls and prostate cancer: population-based prospective cohort and experimental studies
    Ali, Imran
    Julin, Bettina
    Glynn, Anders
    Hogberg, Johan
    Berglund, Marika
    Johansson, Jan-Erik
    Andersson, Swen-Olof
    Andren, Ove
    Giovannucci, Edward
    Wolk, Alicja
    Stenius, Ulla
    Akesson, Agneta
    [J]. CARCINOGENESIS, 2016, 37 (12) : 1144 - 1151
  • [2] [Anonymous], UROL ONCOL
  • [3] [Anonymous], BRIEF BIOINFORM
  • [4] [Anonymous], 2019, J CELL MOL MED, DOI DOI 10.1111/jcmm.14791
  • [5] Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial
    Armstrong, Andrew J.
    Anand, Aseem
    Edenbrandt, Lars
    Bondesson, Eva
    Bjartell, Anders
    Widmark, Anders
    Sternberg, Cora N.
    Pili, Roberto
    Tuvesson, Helen
    Nordle, Orjan
    Carducci, Michael A.
    Morris, Michael J.
    [J]. JAMA ONCOLOGY, 2018, 4 (07) : 944 - 951
  • [6] Systemic alkalinisation delays prostate cancer cell progression in TRAMP mice
    Astigiano, Simonetta
    Puglisi, Andrea
    Mastracci, Luca
    Fais, Stefano
    Barbieri, Ottavia
    [J]. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017, 32 (01) : 363 - 368
  • [7] Systems medicine: the future of medical genomics and healthcare
    Auffray, Charles
    Chen, Zhu
    Hood, Leroy
    [J]. GENOME MEDICINE, 2009, 1
  • [8] Impact of Age at Diagnosis on Prostate Cancer Treatment and Survival
    Bechis, Seth K.
    Carroll, Peter R.
    Cooperberg, Matthew R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 235 - 241
  • [9] Impact of age at diagnosis of de novo metastatic prostate cancer on survival
    Bernard, Brandon
    Burnett, Colin
    Sweeney, Christopher J.
    Rider, Jennifer R.
    Sridhar, Srikala S.
    [J]. CANCER, 2020, 126 (05) : 986 - 993
  • [10] Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction
    Bidarra, David
    Constancio, Vera
    Barros-Silva, Daniela
    Ramalho-Carvalho, Joao
    Moreira-Barbosa, Catarina
    Antunes, Luis
    Mauricio, Joaquina
    Oliveira, Jorge
    Henrique, Rui
    Jeronimo, Carmen
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9